FISH-Based Test Identify Genetic Abnormalities in Plasma Cell Malignancies
Filed in archive Diagnostics, Methodologies and Instrumentation , Genomics, Proteomics and Bioinformatics on October 28, 2007
Mayo Clinic researchers have developed a chromosome FISH-based test which surpasses conventional methods in identifying chromosomal genetic abnormalities associated with plasma cell malignancies and thus help physicians better assess a patient's prognosis and likelihood to respond to a given treatment. Plasma cell proliferative disorders, or PCPD, account for approximately 10 percent of all blood born cancers.
The FISH test is designed to detect genetic abnormalities in plasma cells whereas other conventional methods typically looks within any cell type that is present.
The test should be applied to patients diagnosed with PCPD, particularly multiple myeloma, to determine the presence of genetic abnormalities that could offer insight into prognosis, he states.
Source: Mayo Clinic

The test should be applied to patients diagnosed with PCPD, particularly multiple myeloma, to determine the presence of genetic abnormalities that could offer insight into prognosis, he states.
Tags: FISH genetics genomics cancer diagnostics biotech genetic+abnormalities plasma+cell
Vote for FISH-Based Test Identify Genetic Abnormalities in Plasma Cell Malignancies:
|
Rating: 8.33 out of 6 vote(s) cast.
|
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells
